Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Alcon claims three series of 5-HT2 agonists with utility in glaucoma therapy

Jan. 23, 2003

Novartis obtains rights to pirenzepine for myopia from Valley Forge

Jan. 20, 2003

InSite Vision finalizes ISV-401 phase III trial protocol

Jan. 20, 2003

Inspire prepares to submit NDA for diquafosol by mid-2003

Jan. 14, 2003

Restasis receives FDA approval

Jan. 7, 2003

FDA approval for Xalatan as first-line therapy for elevated IOP

Jan. 2, 2003

Pfizer and Eyetech form collaboration to develop and commercialize Macugen

Dec. 30, 2002

Statistically significant preliminary results in Visudyne study in minimally classic wet AMD

Dec. 27, 2002

Moxifloxacin NDA filed for bacterial conjunctivitis and ophthalmia neonatorum

Dec. 20, 2002

Advanced Biotherapy prepares IND for corneal transplant rejection therapy

Dec. 11, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...